We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.
The trial will use innovative screening methods like an MRI scan and see hundreds of thousands of men across the country participating.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
These documents describe the NHS prostate cancer risk management programme (PCRMP) and its associated prostate specific antigen (PSA) test.
This prostate cancer risk management programme (PCRMP) information is to help GPs advise men aged 50 and over who ask about prostate specific antigen (PSA) testing.
This information aims to support GPs to give clear and balanced advice to men without symptoms of prostate disease who ask about PSA testing.
NHS prostate cancer risk management programme (PCRMP) guidance on performing an ultrasound-guided prostate biopsy.
This document contains a synopsis of causation occurring in cancer of the prostate.
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
The Advisory Committee on Releases to the Environment's advice on an application for a trial of a genetically modified cancer vaccine.
A statement from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
The MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion)
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).